You are about to leave HUTCHMED's website and enter a third-party website not operated by HUTCHMED. We do not control or hold responsibility for any information contained or collected by third party websites. You should exercise caution and look at the privacy statement applicable to the website in question. Do you wish to proceed?

您即将离开和黄医药官网，并前往非和黄医药运营的第三方网站。我们不对第三方网站发布或收集的信息拥有控制权或承担任何责任。我们建议您仔细阅读这些网站的隐私政策。您确定要继续吗?

ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors